N@N

Data on Lead Anticancer Compounds Perifosine and AEZS-108 to be Presented at Upcoming ASCO Annual Meeting

_{//health-fitness.news-articles.net/content/2010/ .. e-presented-at-upcoming-asco-annual-meeting.html}
^{Published in Health and Fitness on Friday, May 21st 2010 at 5:45 GMT by Market Wire}  

 Perifosine ---------- Abstract No. 9540: "Phase I Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors" Lead Author: Oren J. Becher, MD, Memorial Sloan-Kettering Cancer Center Presenter: Mark Kieran, MD, PhD, Dana-Farber Cancer Institute Date and Time: Sunday, June 6, 2010, 2 pm-6 pm (poster discussion 5:40pm-6pm) Poster Board No.: 42b Location: S Hall A2 (poster discussion in S504) Abstract No. 3531: "Final results of a randomized Phase II study of perifosine in combination with capecitabine (P-CAP) vs. placebo plus capecitabine (CAP) in patients (pts) with second or third line metastatic colorectal cancer (mCRC)" Lead Author: Donald A. Richards, MD, PhD, Texas Oncology Presenter: Wells Messersmith, MD, University of Colorado Date and Time: Tuesday, June 8, 2010, 8 am-12 noon (poster discussion 11:45 am-12 noon) Poster Board No.: 22 Location: S403 (poster discussion in S406) AEZS-108 -------- Abstract No. 5035: "Phase 2 study of AEZS-108, a targeted cytotoxic LHRH analog, in patients with LHRH receptor positive platinum resistant ovarian cancer" Lead Author: Prof. Günter Emons, Chairman, Department of Obstetrics & Gynaecology Georg-August University Gottingen, Germany Presenter: Prof. Günter Emons Date and Time: Saturday, June 5, 2010 2pm- 6pm Poster Board No.: 45B Location: S Hall A2